Sumatriptan Succinate

DRUG7 trials

Sponsors

GlaxoSmithKline, NuPathe Inc., Teva Pharmaceuticals USA, NeurAxon Inc.

Conditions

Compare Bioequivalence Patches Previously Used in the NP101-007 StudyHealthyMigraine DisordersMigraine With Aura

Phase 1

Phase I Study to Compare NP101(Sumatriptan Iontophoretic Transdermal Patch) With Three Formulations of Imitrex®

CompletedNCT00546650

NuPathe Inc.Healthy

Start: 2007-11-30End: 2008-03-31Updated: 2016-02-03

Phase I, Open Label, Single-Dose, Four Way Crossover Study to Compare the PK of NP101 With Oral Imitrex® (50mg) in Migraine Subjects During an Acute Migraine Attack and During a Non-Migraine Period

CompletedNCT00723983

NuPathe Inc.Migraine Disorders

Start: 2008-11-30End: 2009-09-30Updated: 2016-02-03

Sumatriptan Succinate 100 mg Tablets Under Fasting Conditions

CompletedNCT00847405

Teva Pharmaceuticals USAHealthy

Start: 2003-03-31End: 2003-03-31Updated: 2009-09-11

Sumatriptan Succinate 100 mg Tablets Under Non-Fasting Conditions

CompletedNCT00846885

Teva Pharmaceuticals USAHealthy

Start: 2004-08-31End: 2004-10-31Updated: 2009-09-11

Compare PK and Bioavailability of 2 NP101 Patches With Oral Imitrex in Healthy Adults

CompletedNCT01381796

NuPathe Inc.Compare Bioequivalence Patches Previously Used in the NP101-007 Study

Start: 2009-12-31End: 2010-09-30Updated: 2017-10-12

Phase 2

Study of NXN 188 for the Treatment of Migraine With Aura

CompletedNCT00920686

NeurAxon Inc.Migraine With Aura

Start: 2009-06-30End: 2010-03-31Updated: 2014-08-11

Phase 3

Study Of Sumatriptan Succinate Injection Kit In Patients With Migraine or Cluster Headache In Japan

CompletedNCT00356603

GlaxoSmithKlineMigraine Disorders

Start: 2006-06-20End: 2006-08-07Updated: 2018-09-04